A rapid rituximab infusion pilot study
Paula Statham Nurse manager, Ambulatory cancer care unit, employed at University College London Hospitals NHS Foundation Trust, London
Catherine Demosthenous Nurse manager, Ambulatory cancer care unit, employed at University College London Hospitals NHS Foundation Trust, London
Simon Cheesman Haematology pharmacist, Employed at University College London Hospitals NHS Foundation Trust, London
Helen Keane Day care nurse manager, Employed at University College London Hospitals NHS Foundation Trust, London
Given the extended license for rituximab (MabThera) and the anticipated increase in demand for its use in chemotherapy units, a pilot study investigating its rapid infusion was carried out in the haematology unit of a London cancer centre. The study revealed that 90 minute rapid rituximab infusions may be administered safely during second and subsequent treatments to eligible patients. This finding may have significant implications for day care resources, appointment scheduling and patient satisfaction, and therefore warrants further investigation
Cancer Nursing Practice.
5, 6, 35-38.
doi: 10.7748/cnp2006.07.5.6.35.c7580
Want to read more?
Already have access? Log in
or
3-month trial offer for £5.25/month
Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
- Unlimited access to all 10 RCNi Journals
- RCNi Learning featuring over 175 modules to easily earn CPD time
- NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
- Personalised newsletters tailored to your interests
- A customisable dashboard with over 200 topics
Subscribe
Alternatively, you can purchase access to this article for the next seven days.
Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
